(E,E)-bisantrene Discovered to Function via Silencing of c-MYC Expression
Preclinical studies have highlighted how (E,E)-bisantrene silences c-MYC gene expression via G4-DNA binding and stabilization leading to clinically relevant and broad anticancer activity SYDNEY, May 6, 2026 /PRNewswire/ -- Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical company, reports the discovery of the primary mechanism of action (MOA) of its lead oncology asset, (E,E)-bisantrene. Bisantrene has a long...
China Medical Exhibition 2026: Industries, Products, and Innovations to Watch
SHANGHAI, May 6, 2026 /PRNewswire/ -- The medical device industry moves fast. To stay competitive, you must source the best materials and adopt the latest manufacturing technology before your rivals do. Medtec China serves as the ultimate proving ground for these breakthroughs. As Asia's premier event dedicated exclusively to medical device research, development, and manufacturing, it offers unmatched access to...
The GBA Healthcare Group and Adventist Health Hong Kong Forge Strategic Partnership for Seamless Specialty Care
Pooling Guangdong–Hong Kong clinical strengths to deliver an end-to-end cross-border care ecosystem spanning direct billing, fast-track referrals and precision specialty matching HONG KONG, May 6, 2026 /PRNewswire/ -- The GBA Healthcare Group ("GBAH") and Adventist Health Hong Kong ("AHHK") today announced a strategic partnership that introduces cross-border direct billing, a dedicated medical green channel, and precision specialty referrals —...
Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia
SHANGHAI, May 6, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, today announced the completion of patient enrollment in the global Phase III pivotal multi-regional clinical trial (RESPOND-2, Study AP301-HP-03) of AP301, a novel fiber-iron-based phosphate binder,...
Nona Biosciences Evolves Brand to Reflect Next Phase of Growth in Biotherapeutic Innovation
CAMBRIDGE, Mass., May 6, 2026 /PRNewswire/ -- Nona Biosciences, a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, announced the launch of its updated global brand identity, marking an important step in the company's continued expansion and evolution as a partner in biotherapeutic innovation. The refreshed identity reflects Nona's growth...
MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
GUANGZHOU, China, May 6, 2026 /PRNewswire/ -- MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results from its Phase II clinical trial of QA102 in patients with intermediate dry age-related macular degeneration (AMD). Results of the study were presented in an oral presentation at the...
Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
HONG KONG, May 6, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the 33rd European Congress on Obesity (ECO 2026), taking place May 12-15, 2026 in Istanbul, Türkiye. The presentations include a poster on the Phase I data of ASC47, an adipose-targeting...
ESOC 2026: Rising stroke rates highlight widening ethnic and socioeconomic inequalities across populations, major study finds
MAASTRICHT, Netherlands, May 6, 2026 /PRNewswire/ -- A new study presented today at the European Stroke Organisation Conference (ESOC) 2026 shows that after decades of decline, stroke incidence is rising again, driven by higher rates in some ethnic minority populations and concentrated among socioeconomically disadvantaged groups. These findings reflect broader patterns seen in diverse urban populations internationally, pointing to widening...
Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1
PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours TGA registration provides an approved treatment option in an area of significant unmet medical need for children receiving cisplatin chemotherapy ...
CAI Launches Next Chapter with Investment from JLL Partners
INDIANAPOLIS, May 5, 2026 /PRNewswire/ -- CAI, a professional services firm dedicated to accelerating operational readiness and excellence in life sciences and mission-critical environments, today announced that it has entered into an agreement with JLL Partners, a New York-based middle-market private equity firm focused on investing in the healthcare, industrials, and business services sectors, to...
